LymphomaArchives
Fine Needle Aspiration of CD20‐Negative Diffuse Large B Cell Lymphoma Presenting as an Anterior Neck Mass
Lymphoma 2 min.
High‐grade lymphoma of the neck can swiftly cause airway compromise, and therefore prompt diagnoses are vital. Fine needle aspiration cytology (FNAC) can quickly differentiate lymphoma from other malignancies and can often subtype it [1]. Diffuse large B cell lymphoma (DLBCL) is aggressive but...
From virus to cancer: Epstein–Barr virus miRNA connection in Burkitt's lymphoma
Lymphoma 8 min.
Burkitt lymphoma (BL) is a highly aggressive form of non-Hodgkin lymphoma that is characterized by its rapid growth and association with EBV infection. EBV, a widely prevalent human herpesvirus, has been linked to the development of BL. among the repertoire of EBVs, microRNAs (miRNAs) have been identified...
External validation and calibration of the HoLISTIC Consortium's advanced‐stage Hodgkin lymphoma international prognostic index (A‐HIPI) in the Brazilian Hodgkin lymphoma registry
Lymphoma 4 min.
Classical Hodgkin lymphoma (cHL) is a B‐cell malignancy that typically affects young adults. In recent decades, significant advancements have been achieved in the treatment of cHL, making it one of the most curable cancers, with more than 80% of patients being cured of the disease. The challenge...
Time to lymphoma treatment within 24 months in ‘watch and wait’ follicular lymphoma is associated with inferior outcomes: A multicentre analysis
Lymphoma 5 min.
Follicular lymphoma (FL) is the most common indolent non‐Hodgkin lymphoma, characterised by a prolonged, relapsing–remitting and incurable course. FL is also a clinically and molecularly heterogeneous disease. Some of them are at risk of early mortality due to early progression after immunochemotherapy...
The future of immunotherapy for diffuse large B‐cell lymphoma
Lymphoma 6 min.
First‐line R‐CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) and similar regimens are curative in 60%–70% of patients with diffuse large B‐cell lymphoma (DLBCL), with 30%–40% of patients experiencing relapse or a primary refractory disease...
